FDA Approval Process: How GLP-1 Medications Get to Market

Introduction

The FDA drug approval process takes about 8 to 12 years and costs roughly $2 to $3 billion per approved drug. For GLP-1 medications, the process started decades ago with discovery work on the incretin system and ended with the high-profile approvals of Wegovy® in 2021 and Zepbound® in 2023.

Understanding the approval process matters because it shapes what we know about a drug. FDA-approved medications have been through extensive clinical testing with documented safety and efficacy. Compounded versions of FDA-approved active ingredients exist in a different regulatory space, with their own rules under sections 503A and 503B of the federal Food, Drug, and Cosmetic Act.

The path from molecule to market includes preclinical research, three phases of human trials, NDA submission, FDA review, and post-approval monitoring. Each step has specific requirements and timelines.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Does the FDA Do?

The Food and Drug Administration is a federal agency under the Department of Health and Human Services. Its core mission is to protect public health by ensuring the safety and efficacy of drugs, biologics, medical devices, food, and certain other products.

Quick Answer: FDA approval takes 8-12 years and requires extensive clinical trial evidence

For drugs, the FDA reviews evidence of safety and effectiveness before allowing them to be marketed in the United States. The agency also regulates manufacturing standards, labeling, and post-marketing surveillance.

The Center for Drug Evaluation and Research (CDER) is the FDA division that reviews new drug applications. Within CDER, specific divisions focus on therapeutic areas like cardiovascular, oncology, and endocrinology and metabolism.

What Is Preclinical Research?

Before a drug can be tested in humans, it must show evidence of safety and biological activity in laboratory and animal studies. This is the preclinical phase, which typically lasts 3 to 6 years.

Preclinical work includes pharmacology (how does the drug work biologically), pharmacokinetics (how is it absorbed, distributed, and eliminated), toxicology (what doses cause harm in animal models), and manufacturing (can it be made consistently with high purity).

Semaglutide preclinical work started in the early 2000s at Novo Nordisk, building on prior research on liraglutide and native GLP-1 biology. The molecule was engineered to extend half-life from 2 minutes to over a week, allowing once-weekly dosing.

What Is an IND Application?

The Investigational New Drug (IND) application is the formal request to begin human testing. The sponsor submits preclinical data, manufacturing information, and proposed protocols for phase 1 trials. The FDA has 30 days to review and either object or allow the trials to proceed.

For most new drugs, the IND opens the door to phase 1 dosing studies. These first-in-human trials are typically conducted in healthy volunteers under careful monitoring.

The IND remains active throughout the drug development program. Updates and amendments are filed as new trials begin and new safety data emerges.

What Happens in Phase 1 Trials?

Phase 1 tests safety and pharmacokinetics in a small group of subjects, usually 20 to 100. For most drugs, the subjects are healthy volunteers. For drugs with significant toxicity (like cancer chemotherapy), patients with the target condition may be used.

The main goals are to identify the maximum tolerated dose, characterize drug absorption and elimination, and detect any major safety signals. Phase 1 typically lasts 6 to 12 months and costs about $1 to $5 million.

For GLP-1 drugs, phase 1 trials established dosing ranges that would later be tested in larger efficacy studies. Side effects like nausea were identified and characterized at this stage.

What Happens in Phase 2 Trials?

Phase 2 tests preliminary efficacy and refines dosing in patients with the target condition. Studies typically enroll 100 to 500 patients and last 1 to 2 years.

Phase 2 trials often use multiple doses to identify the dose-response relationship. For obesity drugs, phase 2 trials measure weight loss over 24 to 52 weeks and compare different doses to placebo.

The 2018 phase 2 trial of semaglutide for obesity (O’Neil et al. 2018, Lancet) tested doses from 0.05 mg to 0.4 mg daily and identified the dose range that would be tested in phase 3. The trial showed dose-dependent weight loss reaching 13.8% at the highest dose.

What Happens in Phase 3 Trials?

Phase 3 is the key efficacy testing. Trials enroll 1,000 to 5,000 or more patients across multiple sites, often in multiple countries. Duration is typically 1 to 3 years.

Phase 3 trials are the basis for FDA approval. They must demonstrate that the drug works for its intended indication and that the benefits outweigh the risks. Multiple phase 3 trials are usually required.

For semaglutide in obesity, the STEP program included STEP 1 (general obesity), STEP 2 (diabetes plus obesity), STEP 3 (with intensive behavioral therapy), STEP 4 (continuation versus withdrawal), STEP 5 (long-term), STEP 6 (East Asian population), STEP 7 (with renal impairment), and STEP 8 (head-to-head versus liraglutide). The package showed effects across populations and conditions.

What Is the NDA?

The New Drug Application is the formal request for FDA approval. The sponsor submits all data from preclinical and clinical studies, manufacturing details, proposed labeling, and risk management plans. NDAs are typically 100,000+ pages of documents.

The FDA reviews the NDA and decides whether to approve, deny, or request additional information. Standard review takes 10 to 12 months from submission to decision. Priority review for drugs treating serious conditions takes about 6 months.

For Wegovy, Novo Nordisk submitted the NDA in late 2020 based on STEP 1 through STEP 4 data. The FDA approved the drug in June 2021 for chronic weight management in adults with obesity or overweight with weight-related conditions.

What Is 505(b)(2)?

The 505(b)(2) pathway allows applicants to submit an NDA that relies in part on studies they did not conduct themselves. It is most commonly used for new dosage forms, new indications, or new combinations of approved drugs.

Saxenda® (liraglutide for obesity) was approved through 505(b)(2) based largely on the existing safety data from Victoza® (liraglutide for diabetes), with new efficacy trials in obesity. This shortened the development timeline by using existing data on the same molecule.

The 505(b)(2) pathway has supported faster expansion of GLP-1 medications into new indications. It is distinct from the 505(b)(1) full NDA used for new molecular entities.

Key Takeaway: Semaglutide was first approved in 2017 for diabetes, then 2021 for weight loss

What Is Post-approval Surveillance?

After approval, drugs continue to be monitored in real-world use. Phase 4 trials may be required by the FDA. Post-marketing reporting captures adverse events that are too rare to detect in pre-approval trials.

The MedWatch program collects adverse event reports from clinicians, pharmacists, and patients. Signal detection in these reports can prompt label updates, restrictions, or in rare cases withdrawal.

For semaglutide, post-marketing data has continued to be collected through the SELECT cardiovascular outcomes trial, the FLOW kidney outcomes trial, the SUSTAIN-FORTE high-dose trial, and many other programs. The drug has been studied in more patients post-approval than most medications.

How Does Compounding Fit In?

Compounding is a separate regulatory pathway under sections 503A and 503B of the FDCA. Compounded medications are prepared by licensed pharmacies to meet specific patient needs that cannot be met by FDA-approved commercial products.

503A compounding is patient-specific and requires a prescription. 503B compounding is by outsourcing facilities registered with the FDA that can produce larger batches under stricter manufacturing standards.

Compounded semaglutide and tirzepatide became widely available during the FDA-declared shortage of branded products. With the shortage ending in 2025, the rules have shifted. Personalized compounding for specific clinical needs continues under 503A and 503B pathways.

How Does TrimRx Work Within FDA-regulated Pathways?

TrimRx works with FDA-registered compounding pharmacies that follow USP standards for sterile preparations. The compounded semaglutide and tirzepatide formulations use pharmaceutical-grade active pharmaceutical ingredients from licensed suppliers.

A free assessment quiz starts the clinical review. Clinicians evaluate appropriateness, prescribe individualized doses, and monitor response over time. The personalized treatment plan operates within the legitimate compounding framework.

What Is Breakthrough Therapy Designation?

Breakthrough therapy is an FDA designation that provides expedited development and review for drugs treating serious conditions where preliminary evidence shows substantial improvement over existing therapies. The designation includes intensive FDA guidance and rolling review.

Several GLP-1 medications have received breakthrough designations for specific indications. The designation does not change the evidence requirements for approval but can shorten the development timeline by months to years.

Other expedited pathways include fast track, priority review, and accelerated approval. Each has specific criteria and benefits. Drugs treating obesity have generally not used these pathways aggressively because the FDA does not classify obesity itself as a life-threatening condition.

How Does the FDA Monitor Drug Safety After Approval?

Post-marketing surveillance includes the MedWatch reporting system, mandatory pharmacovigilance from manufacturers, and active surveillance through claims data systems like the FDA Sentinel program.

For high-priority safety signals, the FDA can require additional studies, label updates, or restricted use. Black box warnings, the most severe label warnings, are added when serious safety concerns emerge.

GLP-1 medications have ongoing safety monitoring across multiple programs. The medullary thyroid carcinoma signal, pancreatitis concerns, gallbladder disease, and other potential issues are being tracked through both passive reporting and active surveillance.

What Is the Difference Between Approval and Label Updates?

Initial approval covers a specific indication, patient population, and dosing. Subsequent label updates can expand approved uses, modify dosing recommendations, or add new safety information.

For semaglutide, the initial 2017 approval was for type 2 diabetes at lower doses. Subsequent approvals added obesity (Wegovy 2021), cardiovascular benefit labeling (SELECT-based 2024), and other indications. Each label update required additional trial evidence.

Label updates can be initiated by manufacturers seeking expanded use or by the FDA based on safety signals. The process involves submission of supporting data and FDA review.

How Does Compounding Intersect with Approved Drugs?

Compounding pharmacies can prepare medications based on FDA-approved active ingredients when specific patient needs cannot be met by commercial products. These needs include unavailable strengths, allergies to inactive ingredients, or pediatric dosing.

During FDA-declared shortages, compounding pharmacies can also prepare versions of drugs that are otherwise commercially available. This pathway became important for GLP-1 medications during 2022-2024 shortages.

With shortages now resolved for most GLP-1 products, the compounding landscape has shifted. Personalized compounding for specific patient needs under 503A and 503B continues but the rules around bulk compounding of commercially available products have tightened.

Bottom line: Compounding under 503A/503B follows different rules from new drug approval

FAQ

How Long Does FDA Approval Take?

The full development cycle from preclinical to approval typically takes 8 to 12 years. Accelerated and breakthrough designations can shorten this for some drugs.

What Is the Difference Between FDA-approved and FDA-cleared?

Approval applies to drugs and high-risk devices. Clearance applies to lower-risk medical devices. The terms are not interchangeable.

Why Was Wegovy Approved Separately From Ozempic®?

Same molecule (semaglutide), different doses and indications. Wegovy is approved for chronic weight management at 2.4 mg; Ozempic is approved for type 2 diabetes at lower doses.

What Is the Breakthrough Therapy Designation?

A designation that gives the FDA additional flexibility to expedite development and review of drugs treating serious conditions where preliminary clinical evidence shows substantial improvement over existing therapies.

Are Compounded Drugs FDA-approved?

Compounded medications are not FDA-approved as finished products. They are prepared by licensed pharmacies under different regulatory authority for patient-specific needs.

What Happens If the FDA Finds a Safety Problem After Approval?

The agency can require label changes, restrict use, mandate additional studies, or in rare cases withdraw the drug from market.

How Does the FDA Decide What Is Enough Evidence?

The agency weighs the magnitude of benefit, the severity of the condition, and the safety profile. Drugs for serious conditions can be approved with less evidence than drugs for milder problems.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.